<DOC>
	<DOCNO>NCT02234115</DOCNO>
	<brief_summary>The study evaluate Leuprolide Mesylate safe effective treatment subject advance prostate carcinoma , administer two injection six month apart .</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacokinetic Behavior Leuprolide Mesylate Subjects With Advanced Prostate Carcinoma</brief_title>
	<detailed_description>This multi-center , open-label , single-arm study conduct 2 part . Part I establish provide vanguard first 30 subject frequent monitoring safety . If safety establish , remainder subject enter clinical study ( i.e. , Part II ) . All subject male advance prostate carcinoma judge candidate medical androgen ablation therapy , receive two injection LMIS 50 mg six-month apart unblinded fashion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Males age ≥ 18 year old 2 . Males histologically confirm carcinoma prostate 3 . Subjects judge attend physician and/or Principal Investigator candidate androgen ablation therapy 4 . Baseline morning serum testosterone level &gt; 150 ng/dL perform Screening Visit 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance score ≤ 2 6 . Life expectancy least 18 month 7 . Laboratory value Absolute neutrophil count ≥ 1,500 cells/µL Platelets ≥ 100,000 cells/µL Hemoglobin ≥ 10 gm/dL Total bilirubin ≤ 1.5 × upper limit normal ( ULN ) AST ( SGOT ) ≤ 2.5 × ULN ALT ( SGPT ) ≤ 2.5 × ULN Serum creatinine ≤ 1.5 mg/dL Lipid profile within acceptable range accord investigator 's judgment HgbA1c within acceptable range accord investigator 's judgment Clinical chemistry ( K , Na , Mg , Ca P ) within acceptable range accord investigator 's judgment Serum glucose within acceptable range accord investigator 's judgement Urinalysis within normal range accord investigator 's judgment 8 . Agree use male contraceptive method study trial 9 . Based Investigator 's judgment , ability understand nature study hazard participation , communicate satisfactorily Investigator participate , comply , requirement entire protocol 10 . All aspect protocol explain write informed consent obtain Receipt chemotherapy , immunotherapy , cryotherapy , radiotherapy , anti androgen therapy concomitantly , within 8 week prior Screening Visit , treatment carcinoma prostate . Radiation pain control allow study . Receipt vaccination ( include influenza ) within 4 week Baseline History blood donation within 2 month Baseline History anaphylaxis LHRH analogues Receipt LHRH suppressive therapy within 6 month Baseline Major surgery , include prostatic surgery , within 4 week Baseline History concomitant clinical radiographic evidence central nervous system/spinal cord metastasis . Subjects risk spinal cord compression exclude . Clinical evidence active urinary tract obstruction subject risk urinary obstruction History bilateral orchiectomy , adrenalectomy , hypophysectomy History presence hypogonadism , receipt exogenous testosterone supplementation within 6 month Baseline Clinically significant abnormal ECG and/or history clinically significant cardiovascular disease judge investigator History drug and/or alcohol abuse within 6 month Baseline Contraindication leuprolide LHRH agonist indicate package labeling Use 5alpha reductase inhibitor within last 6 month Baseline History presence insulindependent diabetes mellitus ( Type I ) . Presence well control diabetes mellitus Type II allow Use systemic corticosteroid dose &gt; 10 mg/d antiandrogens Use investigational agent within 4 week Baseline Use overthecounter ( OTC ) medication within 4 week Baseline except list permitted Concomitant Treatment section . Uncontrolled intercurrent illness would jeopardize subject 's safety , interfere objective protocol , limit subject 's compliance study requirement , determine Investigator consultation Sponsor</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Prostate Neoplasm Cancer Carcinoma</keyword>
</DOC>